Insider · CIK 0002021679

Patel Naimish

Reports to the SEC for 2 companies · ANTWERPEN

sec.gov

Transactions

Companies

Filings

CIK

0002021679

Forms 4 and 5

Insider transactions

21 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-11	AGMBAgomAb Therapeutics NV · Stock Option (Right to Buy)A Award	Director	AAward	+56.3K sh	—	—	56,328
2026-05-29	CRSPCRISPR Therapeutics AGS Sale	Chief Medical Officer	SSale	−3,786 sh	$55.62	−$211K	19,357
2026-05-29	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Chief Medical Officer	AAward	+22K sh	—	—	22,000
2026-05-28	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+10K sh	—	—	23,143
2026-05-28	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−10K sh	—	—	20,000
2026-03-20	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+38.5K sh	—	—	38,499
2026-03-20	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Chief Medical Officer	AAward	+30K sh	—	—	30,000
2026-03-16	CRSPCRISPR Therapeutics AGS Sale	Chief Medical Officer	SSale	−3,150 sh	$48.26	−$152K	13,143
2026-03-14	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+8,125 sh	—	—	16,293
2026-03-14	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−8,125 sh	—	—	24,375
2025-10-03	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+16.5K sh	—	—	16,500
2025-05-30	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Chief Medical Officer	AAward	+25K sh	—	—	25,000
2025-05-29	CRSPCRISPR Therapeutics AGS Sale	Chief Medical Officer	SSale	−3,932 sh	$35.94	−$141K	6,068
2025-05-28	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+10K sh	—	—	10,000
2025-05-28	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−10K sh	—	—	30,000
2025-04-03	CRSPCRISPR Therapeutics AGP Purchase	Chief Medical Officer	PPurchase	+1,508 sh	$32.96	+$49.7K	1,508
2025-03-14	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+46.7K sh	—	—	46,667
2025-03-14	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Chief Medical Officer	AAward	+32.5K sh	—	—	32,500
2024-10-16	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+18.3K sh	—	—	18,333
2024-05-28	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+85K sh	—	—	85,000
2024-05-28	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Chief Medical Officer	AAward	+40K sh	—	—	40,000

Recent filings

Accepted (ET)
Sep 154
Patel Naimish0001104659-26-107915
SEC(opens sec.gov)
Jun 24
Patel Naimish0001193125-26-253926
SEC(opens sec.gov)
Jun 14
Patel Naimish0001193125-26-251817
SEC(opens sec.gov)
Mar 244
Patel Naimish0001193125-26-122267
SEC(opens sec.gov)
Mar 174
Patel Naimish0001193125-26-111286
SEC(opens sec.gov)
Jan 274
Patel Naimish0001193125-26-024955
SEC(opens sec.gov)
Oct 34
Patel Naimish0001193125-25-230508
SEC(opens sec.gov)
Jun 34
Patel Naimish0000950170-25-081361
SEC(opens sec.gov)
May 304
Patel Naimish0000950170-25-079822
SEC(opens sec.gov)
Mar 184
Patel Naimish0000950170-25-041470
SEC(opens sec.gov)
Oct 184
Patel Naimish0000950170-24-115697
SEC(opens sec.gov)
May 294
Patel Naimish0000950170-24-065943
SEC(opens sec.gov)

Companies

Address

AGOMAB THERAPEUTICS NV POSTHOFLEI 1/6

ANTWERPEN, 2600